A method of treatment of tuberculosis of peripheral lymph nodes |
|
|
IPC classes for russian patent A method of treatment of tuberculosis of peripheral lymph nodes (RU 2190970):
A means to reduce the toxicity of chemically synthesized anti-tb drugs / 2190417
The invention relates to medicine and veterinary
A method of treatment of tuberculosis of the respiratory organs with severe exudative reaction in children / 2189234
The invention relates to medicine, to Institute, to methods of treatment of tuberculosis of the respiratory organs with severe exudative reaction in children
The method of treatment of pulmonary tuberculosis / 2188644
The invention relates to medicine
The way knee arthroplasty in patients undergoing tb drives / 2188588
The invention relates to medicine, Orthopaedics and traumatology, can be used in the prosthetic knee joint in patients undergoing TB drives
 Composition for treatment of pulmonary infections / 2185818
The invention relates to medicine and pharmacology, and relates to a composition for the treatment of pulmonary infections
 Tuberculostatic agent / 2185170
The invention relates to medicine, in particular tuberculosis and concerns chemotherapeutically antibacterial drugs for treatment of tuberculosis
 Composition for treatment of tuberculosis / 2185168
The invention relates to medicine and can be used in the treatment of tuberculosis
 For the treatment of tuberculosis with low complications fibrocycstic / 2185166
The invention relates to medicine, in particular to the treatment for tuberculosis with low fibrocycstic complications, which represents a conjugate isoniazid-dextran with molecular weight of 65-75 KD, of the formula:
 < / BR>where R1-N - glucose balance or polyglucosides the balance indicated on the drawing type; R2- the rest of isoniazid formula  < / BR>or hydroxyl group  Tablet antimicrobial action / 2185165
The invention relates to medicine, namely to the pharmaceutical industry, and can be used for the treatment of diseases that have arisen as a result of tuberculosis and chlamydia infection
 A method of reducing resistance of mycobacterium tuberculosis to rifampicin and ethambutol in the experiment / 2185162
The invention relates to medicine, in particular tuberculosis, and can be used to treat tuberculosis
 The polymer matrix and their use in pharmaceutical compositions / 2190634
The invention relates to the specific polymer matrix is poly(ethylene carbonate resulting)am, the way they are received, the pharmaceutical compositions based on them, intended for the treatment of diseases, such as chronic inflammatory condition
 The new compound of oxovanadium (iv) with isonicotinic acid hydrazide, possessing anti-diabetic action and manifesting antimycobacterial activity / 2190618
The invention relates to new chemical compound, namely the integrated connection of oxovanadium (IV) with isonicotinic acid hydrazide (GINK) of the formula (VO)2(OH)2(GINK-H)2,
 < / BR>which shows antidiabetic and electoral antimycobacterial activity and may find application in medicine  Substituted n-sintramienergetica, having a stimulating effect on intestinal peristalsis / 2190617
The invention relates to medicine, specifically to new substituted N-sintramienergetica, stimulating peristalsis and which may find application in the treatment of intestinal atony
 Bisimido-(1,10)-phenanthroline copper (ii) dichloride, exhibiting antibacterial and antibioticsbuy activity, method of its production / 2190616
The invention relates to coordination compounds of metals exhibiting cytotoxic activity and can be used in medicine and veterinary medicine for the purpose of chemotherapy
 Salt compounds, drug, composition, method of prevention, treatment / 2190615
The invention relates to salts sulfoxides derived, namely the hydrochloride or the fumarate of 1-{ 2-[(2R)-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholine-2-yl] ethyl} Spiro[benzo(C)thiophene-1(3H),4'-piperidine]-(2S)-oxide, which have a good absorption when taken orally and demonstrate excellent antagonistic activity as receptor NK1and receptor NK2
 Analogues of camptothecin, methods for their preparation and pharmaceutical composition based on them / 2190613
The invention relates to novel analogues of camptothecin formula (1), where R1- alkyl, alkylen, quinil, R2, R3, R4- H, halogen, halogenated, alkyl, alkenyl, -(CH2)mOR6, unsubstituted or substituted phenyl or phenylalkyl or R3and R4form together a chain with 3 or 4 members in which there may be elements of CH, CH2, O, N, or NR9, R3-H, halogen, halogenated, alkyl, alkoxy, substituted or unsubstituted phenyl or phenylalkyl, R6-H, alkyl, R9-H, alkyl, R18and R19-H, halogen, alkyl, alkoxy, hydroxy, R20-H, halogen, Rp-H, -C(O)-A-NR22R23where A - alkalinity radical, R22and R23- H, alkyl, m = 0 to 6 if Rp-H, R3and R4together form a chain with 3 or 4 members
 New derivatives of indole-2,3-dione-3-oxime / 2190612
The invention relates to new derivatives of indole-2,3-dione-3-oxime of the formula I
 < / BR>where R1means hydrogen, C1-C6alkyl; R3means Het or a group of the formula  < / BR>where Het means tetrahydrofuryl, which can be substituted one or more times with substituents selected from the group consisting of halogen, C1-C6of alkyl, C1-C6alkoxy and oxo; at least one of R31, R32and R33independently represents hydrogen, C1-C6alkyl or hydroxy WITH1-C6alkyl and at least one of R31, R32and R33independently represents (CH2)nR34where R34represents hydroxyl, carboxyl,1-C6alkoxycarbonyl,3-C7-cycloalkyl-C1-C6-alkoxycarbonyl, isoxazolidine ring which may be substituted one or more times with substituents selected from the group consisting of halogen, C1-C6of alkyl, C1-C6alkoxy, oxo, or СОNR35R36where R35and R36is hydrogen, C1-C6alkyl, гUB>6alkoxycarbonyl,3-C7cycloalkyl-C1-C6-alkoxycarbonyl, or R35and R36together with the N atom to which they are attached, form a saturated 6-membered heterocyclic ring may contain one additional atom On; n represents 0, 1, 2 or 3; R5means phenyl which may be substituted by phenyl or SO2NR51R52where R51and R52each independently mean C1-C6alkyl, or R51and R52together with the N atom to which they are attached, form a saturated 6-membered monocyclic heterocyclic ring; a is a ring condensed with the benzene ring at the positions marked "a" and "b", and formed the following bivalent radicals: a-CH2-NR6-CH2-CH2-b, where R6means1-C6alkyl, or pharmaceutically acceptable salt  Derivatives benzodioxole, benzofuran, dihydrobenzofuran and benzodioxane and compositions containing them / 2190609
The invention relates to new derivatives of benzodioxole, benzofuran, dihydrobenzofuran and benzodioxane or their pharmaceutically acceptable solvate of General formula I
 < / BR>where Q1and Q2every means independently hydrogen or halogen; X is CH2CH or oxygen; Y represents CR3, CR3R4or (CH2)nwith n = 1-4; Z denotes CH2CH or oxygen; R means hydrogen, halogen or alkyl WITH1-4in both cases; m denotes 1 or 2; R1means1-6-alkyl, C3-6-cycloalkyl,1-3-haloalkyl,1-6-alkylamino,2-6alkenyl,1-4-alkoxy(C1-4)alkyl, C1-C4-alkylthio(C1-4)alkyl or triptorelin-C1-4; R2means hydrogen, halogen or C1-4-alkyl; and R3and R4each independently mean hydrogen or C1-4-alkyl, containing pharmaceutical compositions for the treatment of sleep disorders, and disorders associated with disturbance of circadian rhythms Derivatives benzodioxole, benzofuran, dihydrobenzofuran and benzodioxane and compositions containing them / 2190609
The invention relates to new derivatives of benzodioxole, benzofuran, dihydrobenzofuran and benzodioxane or their pharmaceutically acceptable solvate of General formula I
< / BR>where Q1and Q2every means independently hydrogen or halogen; X is CH2CH or oxygen; Y represents CR3, CR3R4or (CH2)nwith n = 1-4; Z denotes CH2CH or oxygen; R means hydrogen, halogen or alkyl WITH1-4in both cases; m denotes 1 or 2; R1means1-6-alkyl, C3-6-cycloalkyl,1-3-haloalkyl,1-6-alkylamino,2-6alkenyl,1-4-alkoxy(C1-4)alkyl, C1-C4-alkylthio(C1-4)alkyl or triptorelin-C1-4; R2means hydrogen, halogen or C1-4-alkyl; and R3and R4each independently mean hydrogen or C1-4-alkyl, containing pharmaceutical compositions for the treatment of sleep disorders, and disorders associated with disturbance of circadian rhythms  How meatotomy / 2190969
|
(57) Abstract: The invention relates to medicine, to tuberculosis, to methods of treatment of tuberculosis of peripheral lymph nodes. First remove the affected peripheral lymph nodes, and then carry out anti-TB chemotherapy. This method allows you to avoid multi-step operations, reduce treatment time and eliminate possible complications of the disease. The invention relates to medicine, namely tuberculosis, and can be used for the treatment of tuberculosis of peripheral lymph nodes /TPLA/. The relevance of the chosen subject of research is that there has been a steady tendency to increase the number of patients TPLO. Diagnosis and treatment of the disease remains a difficult problem /Bellendir E. P., Savin I. A. Tuberculous lymphadenitis as the actual problem of Phthisiology //Probl. tuberc. - 1997. - 4. - S. 43-44/. The basis of the proposed medical complexes is tuberculostatic therapy conducted after the biopsy and histological verification of diagnosis, and then shown in the cases of operations /szczerba B. C., Bellinger E. N., Nadezhnikov A. T. Pathogenesis, early diagnosis, and l is conservative therapy and the place of surgical treatment of tuberculosis of peripheral lymph nodes// proceedings of the 2nd scientific. are the practice. proc. - Saint-Petersburg. - 1996. - 104-106 C./. It is known that a long and often unsuccessful treatment tuberculostatic due to impaired microcirculation, caseous necrosis, fibrosis in the area of lymph nodes. These pathological changes hinder the achievement of adequate drug concentrations at the site of destruction /Bellendir E. N. , Harashina C. I., Vinogradov centuries Modeling and some questions of the pathogenesis of tuberculosis of lymph nodes// TB and ecology. - 1995. - 4 - C. 19-20/. These data are a prerequisite for the implementation of early operations with suspected or presence of TPLO. The closest analogue is the work Makarova c.u Terms of treatment and follow-up of patients operated on for tuberculosis of peripheral lymph nodes// Probl. tuberc. - 1997. - 2. - S. 14-17/. The author traced the benefits of a comprehensive treatment of TPLO compared with conservative therapy. During examination of the patient was performed by puncture or operating lymph node biopsy to confirm the diagnosis. Then within 2 months spent tuberculostatic therapy against this background made the surgery to remove affected limfaticheskikh indicators in patients undergoing surgery and took tuberculostatic drugs amounted to 1 year. Patients who received only conservative therapy, was treated two years. The disadvantages of the method. As in all known methods of treatment, previously conducted a biopsy of a lymphonodus, pending confirmation of diagnosis histological examination 2 weeks, and bacteriological up to 3 months. Then assign within 2 months of chemotherapy, and only then perform surgery to remove the affected lymph nodes. Thus the center of destruction evacuate no earlier than 2.5 months from receipt of the patient. In this way Pets multistage operation, there are relapses of the disease, surgical allowance is only in case of failure of conservative therapy. The purpose of this proposal is to increase the efficiency of treatment of patients, TPLO by early removal of infected tuberculous process of lymph nodes with subsequent chemotherapy. The task is achieved by the fact that a patient with localized and uncomplicated, TPLO without prior surgical biopsy and chemotherapy produce operation - the lad with the purpose of removal of lymph nodes, and ZAT is logical and bacteriological study. The method allows to avoid multi-step operations and complications, to accelerate the onset of treatment and to reduce the period of time, and also helps to achieve not only therapeutic, diagnostic effect /histological and bacteriological examination preparation distant lymph nodes gives the opportunity to verify the diagnosis. The method is as follows. Patient tuberculous lymphadenitis in the first week of the standard examination to determine the activity of adenozindezaminazy serum - ADA /Titarenko O. T. and other problems. tuberc. - 1998. - 2. - S. 25-27/. High diagnostic efficacy of the test ADA - 88% avoids operating the biopsy and reduce the duration of pre-operative examination. Remove the affected lymph nodes and assign standard TB therapy. The proposed method was treated 22 patients with TPLO. In the nearest and distant /over 3 years/ the results of treatment of complications and exacerbations were observed in patients was not enlarged peripheral lymph nodes, clinical and laboratory data has remained normal the whole time of observation. Differences in clinical and supported by pathological diagnosis was not recorded. Example 2. Patient P., aged 27, was admitted 06.02.98, with tuberculous lymphadenitis of the neck, locally determined conglomeration of lymph nodes 4x5 cm, painless. Made a standard examination, the activity level of HELL serum confirmed the presence of specific lesions of the lymph nodes. 18.02.98, made an operation to remove a conglomerate of neck lymph nodes assigned to three anti-TB drugs, postoperative course without complications. Histological examination verified tuberculous lymphadenitis. Discharged 10.06.98, peripheral lymph nodes are not enlarged, clinical and laboratory data consistently normal.
|
![N-[4-(heteroaromatic)phenyl]-heteroarenes](http://img.russianpatents.com/img_data/50/505280-s.gif)